# Sanofi (SNY) — News

SNY · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/sny/news

## Recent headlines

- [Sanofi to seek public payer access for Dupixent in Canada](https://www.ainvest.com/news/sanofi-seek-public-payer-access-dupixent-canada-2610) — AInvest Wire, Oct 15, 2026
- [Recursion Pharmaceuticals - Candidate added to Sanofi pipeline, phase 1 trials expected in 2027](https://www.ainvest.com/news/recursion-pharmaceuticals-candidate-added-sanofi-pipeline-phase-1-trials-expected-2027-2610) — AInvest Wire, Oct 15, 2026
  Recursion Pharmaceuticals, Inc. has announced that one of its drug candidates has been added to Sanofi’s development pipeline, marking a strategic collaboration between the two biopharmaceutical companies. The candidate, which is currently in preclinical development, is expected to enter Phase 1…
- [Recursion announces Sanofi options potential first-in-class immunology development candidate from their collaboration](https://www.ainvest.com/news/recursion-announces-sanofi-options-potential-class-immunology-development-candidate-collaboration-2610) — AInvest Wire, Oct 15, 2026
- [Vir Biotechnology - May receive up to $1.74 bln in additional milestones plus tiered royalties](https://www.ainvest.com/news/vir-biotechnology-receive-1-74-bln-additional-milestones-tiered-royalties-2610) — AInvest Wire, Oct 14, 2026
  Vir Biotechnology, Inc. (Nasdaq: VIR) has entered into a global strategic collaboration with Astellas Pharma Inc. to co-develop and co-commercialize VIR-5500, an investigational prostate-specific membrane antigen (PSMA)-targeted T-cell engager (TCE) for the treatment of prostate cancer. Under the…
- [Sanofi settles EU case over disparagement of vaccine rival](https://www.ainvest.com/news/sanofi-settles-eu-case-disparagement-vaccine-rival-2610) — AInvest Wire, Oct 14, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).